rt an indication for the treatment of these 23 conditions. This draft guidance is intended to serve as a focus for continued discussions among 24 the Division of Bone, Reproductive, and Urologic Products, pharmaceutical companies, the 25 academic community, and the public .3 26 27 This guidance focuses on condi